Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 4.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,132,777 shares of the company's stock after purchasing an additional 83,082 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.55% of Moderna worth $142,533,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Banco Santander S.A. acquired a new position in Moderna during the 3rd quarter valued at about $3,550,000. John G Ullman & Associates Inc. increased its holdings in shares of Moderna by 341.3% during the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company's stock valued at $3,318,000 after acquiring an additional 38,400 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Moderna by 51.8% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 85,473 shares of the company's stock valued at $5,712,000 after purchasing an additional 29,177 shares during the last quarter. Cornerstone Advisors LLC boosted its stake in Moderna by 80.0% in the 3rd quarter. Cornerstone Advisors LLC now owns 1,800 shares of the company's stock worth $120,000 after purchasing an additional 800 shares in the last quarter. Finally, Moors & Cabot Inc. grew its position in Moderna by 18.2% during the 3rd quarter. Moors & Cabot Inc. now owns 54,469 shares of the company's stock worth $3,640,000 after purchasing an additional 8,390 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. UBS Group lowered their price objective on shares of Moderna from $140.00 to $108.00 and set a "buy" rating for the company in a research note on Thursday, October 24th. Hsbc Global Res raised Moderna from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Piper Sandler restated an "overweight" rating and issued a $69.00 price objective (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They set an "underperform" rating and a $40.00 target price for the company. Finally, The Goldman Sachs Group cut their price target on shares of Moderna from $178.00 to $139.00 and set a "buy" rating on the stock in a report on Monday, September 16th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and an average price target of $84.00.

Moderna Price Performance

NASDAQ:MRNA traded up $2.55 during trading hours on Monday, reaching $43.66. 15,751,241 shares of the company were exchanged, compared to its average volume of 4,870,879. The firm has a market cap of $16.80 billion, a PE ratio of -7.66 and a beta of 1.69. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47. The stock's 50-day moving average is $54.96 and its 200-day moving average is $93.71. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.39) earnings per share. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO James M. Mock sold 1,321 shares of the company's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company's stock, valued at approximately $682,754. This represents a 13.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold 2,930 shares of company stock worth $217,170 over the last three months. Insiders own 15.20% of the company's stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.